Latest Ratios: P/E Ratio 32.8x · EV/EBITDA 20.4x · ROE 17.8%. (1996–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2.2B | $1.7B | $1.9B | $1.3B | $903M | $535M | $353M | $373M | $223M | $204M | $185M |
| Enterprise Value | $2.4B | $1.9B | $2.1B | $1.4B | $967M | $608M | $331M | $372M | $245M | $166M | $155M |
| P/E Ratio → | 32.77 | 25.32 | 32.26 | 29.51 | 21.63 | 33.62 | 26.33 | 18.86 | 15.56 | 22.06 | 23.14 |
| P/S Ratio | 3.69 | 2.87 | 3.77 | 3.31 | 2.55 | 2.59 | 1.97 | 1.88 | 1.17 | 1.38 | 1.27 |
| P/B Ratio | 5.29 | 4.09 | 5.55 | 4.63 | 3.80 | 2.75 | 1.99 | 2.30 | 1.59 | 1.65 | 1.64 |
| P/FCF | 28.15 | 21.94 | 33.43 | 42.95 | 227.90 | 60.13 | 17.06 | 14.65 | 14.04 | 28.78 | 88.17 |
| P/OCF | 24.19 | 18.85 | 28.58 | 32.05 | 50.91 | 37.43 | 14.08 | 11.94 | 10.47 | 11.68 | 19.71 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 3.10 | 4.16 | 3.41 | 2.73 | 2.95 | 1.84 | 1.88 | 1.29 | 1.12 | 1.06 |
| EV / EBITDA | 20.37 | 16.13 | 21.92 | 19.77 | 14.38 | 20.53 | 13.22 | 11.32 | 8.93 | 9.58 | 8.65 |
| EV / EBIT | 25.53 | 20.22 | 25.85 | 23.73 | 17.43 | 28.63 | 20.20 | 15.30 | 11.87 | 14.11 | 12.49 |
| EV / FCF | — | 23.64 | 36.81 | 44.28 | 244.02 | 68.36 | 15.99 | 14.62 | 15.42 | 23.42 | 73.64 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 28.3% | 28.3% | 29.1% | 28.1% | 25.5% | 24.8% | 24.9% | 27.2% | 25.4% | 24.0% | 23.7% |
| Operating Margin | 15.3% | 15.3% | 16.0% | 14.4% | 15.7% | 10.3% | 9.3% | 12.5% | 10.3% | 7.9% | 8.4% |
| Net Profit Margin | 11.3% | 11.3% | 11.7% | 11.2% | 11.8% | 7.7% | 7.5% | 10.0% | 7.5% | 6.2% | 5.5% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 17.8% | 17.8% | 18.8% | 17.2% | 19.3% | 8.6% | 7.9% | 13.1% | 10.8% | 7.8% | 7.4% |
| ROA | 10.6% | 10.6% | 11.4% | 11.5% | 11.7% | 5.9% | 6.8% | 10.4% | 8.7% | 6.9% | 6.4% |
| ROIC | 12.7% | 12.7% | 14.1% | 13.8% | 14.6% | 7.5% | 7.9% | 11.4% | 11.9% | 10.4% | 11.6% |
| ROCE | 16.1% | 16.1% | 18.0% | 17.3% | 17.9% | 8.8% | 9.3% | 14.5% | 13.2% | 9.5% | 10.8% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.36 | 0.36 | 0.60 | 0.16 | 0.29 | 0.43 | 0.01 | 0.02 | 0.18 | — | 0.01 |
| Debt / EBITDA | 1.33 | 1.33 | 2.15 | 0.67 | 1.02 | 2.85 | 0.09 | 0.09 | 0.92 | — | 0.05 |
| Net Debt / Equity | — | 0.32 | 0.56 | 0.14 | 0.27 | 0.38 | -0.12 | -0.00 | 0.16 | -0.31 | -0.27 |
| Net Debt / EBITDA | 1.16 | 1.16 | 2.01 | 0.59 | 0.95 | 2.47 | -0.88 | -0.02 | 0.80 | -2.19 | -1.71 |
| Debt / FCF | — | 1.70 | 3.38 | 1.32 | 16.12 | 8.23 | -1.07 | -0.03 | 1.38 | -5.36 | -14.53 |
| Interest Coverage | 9.42 | 9.42 | 10.06 | 15.79 | 20.08 | 544.72 | 197.18 | 36.08 | 15.65 | 235.26 | 179.51 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.68 | 2.68 | 2.56 | 2.48 | 2.08 | 2.25 | 4.75 | 3.17 | 2.69 | 7.55 | 7.31 |
| Quick Ratio | 1.52 | 1.52 | 1.41 | 1.28 | 1.12 | 1.39 | 3.52 | 2.08 | 1.75 | 6.26 | 5.83 |
| Cash Ratio | 0.27 | 0.27 | 0.18 | 0.09 | 0.08 | 0.29 | 1.60 | 0.22 | 0.16 | 3.82 | 3.28 |
| Asset Turnover | — | 0.91 | 0.80 | 0.99 | 0.94 | 0.62 | 0.88 | 1.05 | 1.00 | 1.07 | 1.14 |
| Inventory Turnover | 4.98 | 4.98 | 4.09 | 4.10 | 4.92 | 4.64 | 7.23 | 7.90 | 7.26 | 8.73 | 7.88 |
| Days Sales Outstanding | — | 53.42 | 64.88 | 59.98 | 56.86 | 69.67 | 53.78 | 53.22 | 54.28 | 52.79 | 53.07 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 3.1% | 3.9% | 3.1% | 3.4% | 4.6% | 3.0% | 3.8% | 5.3% | 6.4% | 4.5% | 4.3% |
| FCF Yield | 3.6% | 4.6% | 3.0% | 2.3% | 0.4% | 1.7% | 5.9% | 6.8% | 7.1% | 3.5% | 1.1% |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.1% | 0.0% | 0.3% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.1% | 0.0% | 0.3% |
| Shares Outstanding | — | $8M | $8M | $8M | $8M | $8M | $8M | $8M | $7M | $7M | $7M |
Includes 30+ ratios · 30 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying UFPT stock.
UFP Technologies, Inc.'s current P/E ratio is 32.8x. The historical average is 17.6x. This places it at the 96th percentile of its historical range.
UFP Technologies, Inc.'s current EV/EBITDA is 20.4x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 9.1x.
UFP Technologies, Inc.'s return on equity (ROE) is 17.8%. The historical average is 10.3%.
Based on historical data, UFP Technologies, Inc. is trading at a P/E of 32.8x. This is at the 96th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
UFP Technologies, Inc. has 28.3% gross margin and 15.3% operating margin. Operating margin between 10-20% is typical for established companies.
UFP Technologies, Inc.'s Debt/EBITDA ratio is 1.3x, indicating moderate leverage. A ratio below 2x is generally considered financially healthy.
Key Metrics
Top Statement Risk
Customer concentration and EPS miss
Metrics are mathematically derived from official filings.
Premium Multiple for MedTech Pivot
UFPT trades at 36.7x trailing earnings and 22.7x EV/EBITDA, a premium to diversified industrials but below pure MedTech peers, as per recent market data.
The forward P/E of 33.0 implies the market expects continued double-digit earnings growth, consistent with the accelerating medical segment. However, the PEG of 0.97 suggests the growth is not fully priced in, offering potential upside if execution holds. The valuation gap versus peers like Integer Holdings (43.3x P/E) may reflect lingering 'packaging' legacy perceptions, but the medical mix shift supports a re-rating.
Margin Stability Amid Mix Shift
Gross margin held at 29.3% in Q2 2026, near the 30% peak, while operating margin expanded to 16.2%, as reported in the latest quarterly data.
The stability in gross margin despite rising input costs suggests effective cost management and pricing power, likely aided by the higher-margin medical products. Operating margin expansion from 15.1% to 16.2% sequentially indicates operating leverage, but the Q2 EPS miss of $0.06 versus consensus warrants monitoring for cost pressures. Net margin of 12.0% remains healthy, supported by a low tax rate and controlled SG&A.
ROIC Recovery After Acquisition Dip
ROIC improved to 3.6% in Q2 2026 from 2.9% in Q4 2025, but remains below the 4.2% peak in Q3 2024, as per reported figures.
The dip in ROIC following the Q3 2024 acquisition is typical as invested capital expands before earnings fully ramp. The sequential improvement suggests integration is progressing, but the absolute level is modest, reflecting the asset-heavy nature of acquisitions. ROE of 4.6% is stable, indicating that returns are not yet compounding strongly, but the trend is positive.
Working Capital Drag Persists
Cash conversion cycle extended to 107 days in Q2 2026, up from 101 days a year earlier, driven by higher DSO and DIO, as per quarterly data.
DSO rose to 58 days from 49 days in Q3 2024, suggesting slower collections, possibly due to larger OEM customers. DIO remains elevated at 72 days, reflecting inventory build for medical product demand. The negative working capital impact on cash flow in seven of the last ten quarters indicates that efficiency gains are not yet realized, but the current ratio of 3.0 provides ample buffer.
Deleveraging Enhances Flexibility
Debt-to-equity fell to 0.29 in Q2 2026 from 0.69 in Q3 2024, with interest coverage at 16.45x, as per the latest balance sheet data.
The substantial debt reduction from $227.9M to $136.3M over eight quarters reflects strong cash generation and a conservative capital allocation policy. Interest coverage of 16.45x is comfortable, indicating minimal refinancing risk. This low leverage provides capacity for future acquisitions, which are central to the growth strategy, but investors should monitor integration risks.
Solid Liquidity Despite Low Cash
Current ratio improved to 3.00 in Q2 2026, with quick ratio at 1.72, indicating strong short-term coverage, as per recent financial statements.
The current ratio of 3.0 is well above the 2.0 threshold, and the quick ratio of 1.72 suggests that even without inventory, the company can cover near-term obligations. Cash of $9.0M is low, but the undrawn credit facility and strong operating cash flow provide additional flexibility. Under a severe demand shock, the liquidity position appears resilient, though inventory levels could become a drag if sales slow.
Misapplied P/E on Acquisition-Driven Earnings
The P/E ratio is often misapplied to UFPT because acquisition-related amortization and integration costs distort reported earnings, as per financial statement analysis.
UFPT's frequent acquisitions result in significant intangible amortization, which reduces net income and inflates the P/E. A more accurate valuation metric is EV/EBITDA, which excludes depreciation and amortization, or P/FCF, which reflects cash generation. The P/FCF of 31.5x is lower than the P/E of 36.7x, indicating that cash earnings are stronger than accounting earnings. Investors should adjust for one-time costs to assess normalized earning power.